PerkinElmer Launches Clinical Whole Genome Sequencing Services
August 03 2017 - 1:14PM
Business Wire
PerkinElmer Genetics Provides Complete
Genomic Lab Testing Solution
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to
innovating for a healthier world, today announced the launch of
PerkinElmer Genetics’ clinical genomics services. Through its
integrated laboratories in the U.S., India and China, PerkinElmer
offers a global genomic lab testing platform that performs
screening and diagnostic testing, specializing in newborn screening
and high throughput next generation sequencing for rare inherited
diseases.
PerkinElmer Genetics has two state-of-the-art CLIA-certified
clinical laboratories based in Pittsburgh, PA and Branford, CT that
process more than 500,000 samples a year. Their testing menus
include newborn screening, biochemical profiling, 2nd tier
molecular confirmatory testing, Sanger and NGS-based panels, and
exome and genome sequencing.
Today, PerkinElmer Genetics has launched affordable whole exome
sequencing (WES) and whole genome sequencing (WGS) services. These
services are also offered in combination with biochemical profiling
targeted for rapid WES and WGS for genetic disease diagnosis. While
initially focused on our newborn and ViaCord customers, PerkinElmer
Genetics has also developed a biochemical and molecular testing
menu to meet the needs of other segments, such as pharmaceutical
companies, and the markets it serves in China and India.
“We are pleased to extend our portfolio to include clinical WGS
which expands the continuum of care from preconception to newborns.
This offering will provide clinicians insights into the complex
nature of rare and inherited diseases,” said Dr. Madhuri Hegde,
vice president and chief scientific officer for laboratory services
of PerkinElmer’s Diagnostics business group. “Because sequencing is
not a stand-alone option, our ability to use dried blood spot
samples and assimilate molecular and biochemical data from our
global laboratories will improve interpretation of genomic
variants.”
PerkinElmer’s Diagnostics business group focuses on reproductive
health, infectious disease screening and genomics offerings for
oncology and other molecular tests through its broad range of
instruments, reagents, assay platforms and software offerings.
Please visit www.perkinelmergenetics.com for more
information.
About PerkinElmer
PerkinElmer, Inc. is a global leader committed to innovating for
a healthier world. Our dedicated team of 9,000 employees worldwide
is passionate about providing customers with an unmatched
experience as they help solve critical issues especially impacting
the diagnostics, discovery and analytical solutions markets. Our
innovative detection, imaging, informatics and service
capabilities, combined with deep market knowledge and expertise,
help customers gain earlier and more accurate insights to improve
lives and the world around us. The Company reported revenue of
approximately $2.1 billion in 2016, serves customers in more than
150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements relating to
estimates and projections of future earnings per share, cash flow
and revenue growth and other financial results, developments
relating to our customers and end-markets, and plans concerning
business development opportunities and divestitures. Words such as
"believes," "intends," "anticipates," "plans," "expects,"
"projects," "forecasts," "will" and similar expressions, and
references to guidance, are intended to identify forward-looking
statements. Such statements are based on management's current
assumptions and expectations and no assurances can be given that
our assumptions or expectations will prove to be correct. A number
of important risk factors could cause actual results to differ
materially from the results described, implied or projected in any
forward-looking statements. These factors include, without
limitation: (1) markets into which we sell our products declining
or not growing as anticipated; (2) fluctuations in the global
economic and political environments; (3) our failure to introduce
new products in a timely manner; (4) our ability to execute
acquisitions and license technologies, or to successfully integrate
acquired businesses and licensed technologies into our existing
business or to make them profitable, or successfully divest
businesses; (5) our failure to adequately protect our intellectual
property; (6) the loss of any of our licenses or licensed rights;
(7) our ability to compete effectively; (8) fluctuation in our
quarterly operating results and our ability to adjust our
operations to address unexpected changes; (9) significant
disruption in third-party package delivery and import/export
services or significant increases in prices for those services;
(10) disruptions in the supply of raw materials and supplies; (11)
the manufacture and sale of products exposing us to product
liability claims; (12) our failure to maintain compliance with
applicable government regulations; (13) regulatory changes; (14)
our failure to comply with healthcare industry regulations; (15)
economic, political and other risks associated with foreign
operations; (16) our ability to retain key personnel; (17)
significant disruption in our information technology systems; (18)
our ability to obtain future financing; (19) restrictions in our
credit agreements; (20) the approval of the Brexit Referendum in
the United Kingdom; (21) our ability to realize the full value of
our intangible assets; (22) significant fluctuations in our stock
price; (23) reduction or elimination of dividends on our common
stock; and (24) other factors which we describe under the caption
"Risk Factors" in our most recent quarterly report on Form 10-Q and
in our other filings with the Securities and Exchange Commission.
We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170803006076/en/
PerkinElmerBrian Willinsky, +1
781-663-5728brian.willinsky@perkinelmer.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Sep 2023 to Sep 2024